Ohr Pharmaceutical to Present at Upcoming Investment Conferences

NEW YORK, March 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the upcoming 36th Annual Cowen & Company Global Healthcare Conference, and the 28th Annual ROTH Conference.

About Ohr Pharmaceutical, Inc.Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.

Contact:
Ohr Pharmaceutical Inc.                                 LifeSci Advisors, LLC
Investor Relations                                           Michael Wood
888-388-2327                                                  646-597-6983
[email protected]                             [email protected]

You May Also Be Interested In

• CORRECTION – Inventronics Announces 2026 Q2 Financial Results
• Tampa General Hospital Secures Funding to Establish Center for Lymphatic Education and Research
• CISOs Risk MDR Buyer's Remorse Without Clear Procurement Requirements, Says Info-Tech Research Group